Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Imaging of axSpA Remains an Adjunctive Tool

Publish date:: September 16, 2019

Key clinical point: MRI is a valuable but not definitive tool for evaluating axial spondyloarthritis (axSpA), agree both the experts and the data.

Major finding: Reflecting the limits of imaging, 28.1% of 131 patients were diagnosed with axSpA by rheumatologists but not radiologists.

Data source: Prospective analysis of consecutive patients.

Disclosures: Dr. Baraliakos reports extensive financial relationships with pharmaceutical companies. Dr. van Gaalen reports none.

Citation:

Baraliakos X et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):255-6. Abstract OPO344, doi: 10.1136/annrheumdis-2019-eular.5027

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Ankylosing spondylitis

Etanercept may not help some with suspected nonradiographic axial spondyloarthritis,

Novel study explores link between primary immunodeficiencies, rheumatic diseases,

Lower TNF inhibitor efficacy observed in women with nonradiographic axSpA,

Shingrix effective in older adults with preexisting immune-mediated disorders,

Trabecular bone loss may contribute to axial spondyloarthritis progression,